StockData
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Opus Genetics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.82−0.02 (-0.52%)

Close on Oct 19, 2026

Market cap
$425.49M
P/E (TTM)
–
Dividend yield
–

Opus Genetics, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Opus Genetics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.